Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Sandoz International GmbH
Sandoz International GmbH
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Sustainability
Sandoz and Teva achieve independent certification for steps to minimise antimicrobial resistance risk
Certification demonstrates their commitment to protecting people and the planet
Manufacturing
Sandoz opens new packaging centre in Stryków, Poland
The generics division of Novartis has invested €42m in the project
Pharmaceutical
Nick Haggar of Sandoz to become new EGA President
Takes up the role on 8 October
Media
Asia and Latin America will drive biosimilars growth in next decade, says Visiongain
Established players will focus on monoclonal antibodies and licensing deals
Ingredients
Sandoz begins clinical trial of biosimilar rituximab
Aims to demonstrate the bioequivalence of the monoclonal antibody
Regulatory
FDA approves first generic version of Lovenox
Sanofi-aventis has reservations about Sandoz drug for treating DVT
Finance
Sandoz to acquire Oriel Therapeutics
Deal will give Sandoz rights to portfolio of respiratory products targeting asthma and COPD
Subscribe now